Faruqi and Faruqui, LLP Logo
Share this page

In re Niaspan Antitrust Litig., No. 13-cv-1820 (E.D. Pa.)


In the Niaspan case, Faruqi & Faruqi represents a pharmaceutical wholesaler and a proposed class of direct purchasers of Abbott Laboratories’ triglyceride drug, Niaspan, whose active ingredient is niacin (vitamin B6).  Faruqi & Faruqi filed the first direct purchaser complaint in this case.  The case alleges that the successive brand manufacturers of Niaspan (Kos, Abbott, Abbvie) paid successive would-be generic competitors (Duramed, Barr, and Teva) to delay launching less-expensive generic versions of Niaspan, in what is commonly known as a “pay-for-delay” conspiracy.

Contact Counsel

Peter Kohn
Joseph T. Lukens

Faruqi & Faruqi, LLP
101 Greenwood Avenue Suite 600
Jenkintown, PA 19046
Tel: (215) 277-5770


Case Details


  • 04/05/2013

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.